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With thedevelopment ofLX-rayfluorescence(LXRF)tomeasurecortical boneleaddirectly, safely, rapidly,
and noninvasively, the present study was undertaken to a) evaluate LXRF as a possible replacement for the
CaNa2EDTA test; b) quantify lead in tibial cortical bones of mildly to moderately lead-toxic children before
treatment; and c) quantify lead in tibial cortical bones of lead-toxic children sequentially following one to
two courses of chelation therapy. The clinical research design was based upon a longitudinal assessment of
59 untreated lead-toxic children. At enrollment, ifthe blood lead (PbB) was 25 to 55 ,ug/dL andthe erythrocyte
protoporphyrin (EP) concentration was - 35 ,ig/dL, LXRF measurement oftibial bone lead was carried out.
One day later, each child underwent a CaNa,EDTA provocative test. If this test was positive, lead-toxic
children were admitted to the hospital for 5 days ofCaNa2EDTA therapy. These tests were repeated 6 weeks
and 6 months after enrollment. Abatement of lead paint hazards was achieved in most apartments by the
time of initial hospital discharge.
The LXRF instrument consists ofa low energy X-ray generator with a silver anode, a lithium-doped silicon
detector, a polarizer ofincident photons, and a multichannel X-ray analyzer. Partially polarized photons are
directed at the subcutaneous, medial mid-tibial cortical bone. The LXRF spectrum, measured 900 from the
incident beam, reveals a peak in the 10.5 KeV region, which represents the lead La line. The effective dose
equivalent using tissue weighting factors according to guidelines ofthe National Council on Radiation Pro-
tectionandMeasurements (1988), was2.5 ,Sv. Thereproducibility ofreplicateLXRFmeasurements, including
the day-to-day variation ofthe instrument, in 26 lead-toxic children, afterrepositioningthe instrument within
4 cm of the first LXRF measurements, was ± 9.2% (95% confidence limits). For an overlying tibial skin
thickness of5 mm, the minimum detection limit was 7 ,ugoflead/g(wetweight) atthe 95% confidence interval.
Based upon a discriminant analysis, 90% of lead-toxic children were predicted correctly as being Ca-
Na2EDTA-positive or CaNa2EDTA-negative. Using LXRF and PbB values to predict CaNa%EDTA outcomes,
the specificity and sensitivity of these two predictors were 86 and 93%, respectively. In a significant fraction
of CaNa2EDTA-positive and CaNa2EDTA-negative children, cortical bone lead values were similar to lead
concentrations measured via bone biopsy in normal adults and lead workers in industry. By 24 weeks after
enrollment, PbB, EP, and urinary lead/EDTA ratios were similar in all groups. The most dramatic decreases
in net corrected photon counts by LXRF occurred in children treated twice. Mean values of cortical bone
lead by LXRF at 24 weeks in all three groups ofchildren were similar to the mean concentration in untreated
CaNa2EDTA-negative children at enrollment and still three to five times greater than those measured in the
tibia or whole teeth ofnormal European children using atomic absorption. In lead-toxic children who did not
qualify for treatment, additional significant accumulation oflead in bone ended once children were removed
fromleadedenvironmentsorreturnedtolead-abatedapartments. ThesedatasuggestthatLXRFmeasurements
oflead in tibial cortical bone have considerable promise toreplace the CaNa2EDTA test and to provide a more
appropriate end point ofchelation therapy than the conventional indices ofPbB and EP. Moreover, markedly
elevated bone lead values accumulated during early childhood may have an intergenerational impact, as
maternal lead stores amassed during childhood cross the placenta and directly affect the developing fetus.
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the corrected manuscript is being published in its entirety. §Medical Department, Brookhaven National Laboratory, Upton,
*Divisions ofPediatric Metabolism and Epidemiology, Albert Ein- NY 11973.
stein College of Medicine, Montefiore Medical Center, Bronx, NY Addressreprintrequests toJ. F. Rosen, Department ofPediatrics,
10467. Albert Einstein College of Medicine, Monteflore Medical Center, 11i
tDepartment of Radiation Oncology, State University of New East 210th Street, Bronx, NY 10467.
York, Stony Brook, NY 11794.ROSEN ET AL.
Introduction
Leadtoxicity isthe most commonpreventable disease
in preschool children today in the United States. In its
1988 report to Congress, the U.S. Public Health Service
estimated that 5 million or more young children are at
risk from all sources oflead, including paint and lead in
food, drinking water, dust, dirt, and gasoline (1). This
disease is likely to continue for many years because
there are still about 40 million dwellings nationally with
hazardous leaded paint (1).
Neurobehavioral (2,3), cognitive (2,3), developmental
(4,5), and biochemical abnormalities (6) have been dem-
onstrated in childrenwith blood lead (PbB) levels below
25 ,ug/dL, the Centers for Disease Control's current
definition of an upper limit for "normal" PbB values (7).
Present screening and diagnostic techniques cannot
identify large numbers ofasymptomatic lead toxic chil-
dren, many of whom may require chelation therapy.
Erythrocyte protoporphyrin (EP) screening identifies
only about one-half of lead-toxic children who, by def-
inition, have elevated PbB values between 25 and 55
pug/dL (8). Furthermore, the residence halftime oflead
in blood is short and reflects recent exposure (9),
whereas bone lead represents a time-averaged com-
partment of lead with a residence time of months to
years (10).
The decision to proceed with in-hospital chelation
therapy is based upon a positive disodium calcium-ed-
etate (CaNa2EDTA) test (11), which is the current ref-
erence method for assessing total body lead stores (11).
CaNa2EDTA chelates lead from extracellular fluid,
thereby removing lead from hard and soft tissues, in-
cluding blood (12). The CaNa2EDTA test requires a
quantitative 8- to 24-hr urine collection, which is vir-
tually impossible to achieve in large numbers of young
children.
With the recent development ofL X-ray fluorescence
(LXRF) to measure cortical bone lead directly, safely,
rapidly, and noninvasively (13,14,15), the present study
was undertaken to a) evaluate LXRF as a possible re-
placement for the CaNa2EDTA test (13,14); b) quantify
lead in tibial cortical bones ofmildly tomoderately lead-
toxic children before treatment (13,14); and c) quantify
lead in tibial cortical bones of lead-toxic children se-
quentiallyfollowing onetotwo courses ofchelationther-
apy.
Methods
The clinical research design was based upon a lon-
gitudinal assessment of 59 untreated lead-toxic chil-
dren. At enrollment, PbB values were determined. If
the PbB was 25 to 55 ,ug/dL and the EP concentration
in whole blood was
- 35 ,ig/dL, LXRF measurement
of tibial bone lead was carried out (Fig. 1). One day
later, each child underwent a CaNa2EDTA provocative
test. If this test was positive, lead-toxic children were
admitted to the hospital for5 days ofCaNa2EDTA ther-
Untreated Lead-Toxic Children
(BPb: 25-55 gg/dL; EP > 35 ,g/dL)
Longitudinal Design
At Enrollment
BPb, EP
I
LXRF
CaNa2EDTA Test
In-Hospital CaNa2EDTA Therapy Follow-Up
* Repeat testing at 6 weeks, 6 months, 1 year
* On-going abatement in all apartments
* Alternative housing, as indicated
* Repeat in-hospital CaNa2EDTA therapy
predicated upon a positive CaNa2EDTA test
FIGURE 1. Clinical research design.
apy at a daily dose of 1000 mg/rn2 given by continuous
intravenous infusion. These tests were repeated 6
weeks and 6 months after enrollment. During this 6-
month period, if a child qualified for a second provoc-
ative test and a second course of CaNa2EDTA treat-
ment in the hospital, such regimens were carried out.
Abatement of lead paint hazards was achieved in most
apartments by the time ofinitial hospital discharge. In
about 20% ofchildren, alternative housingwas obtained
with family or friends until housing repairs were com-
pleted. By 6 to 8 weeks postenrollment, most of the
major housing repairs had been completed.
The LXRF instrument consists of a low-energy X-
ray generator (Philips Electronics Model #PW1729-25)
with a silver anode, a lithium-doped silicon detector, a
polarizer ofincident photons, and a multichannel X-ray
spectrum analyzer (13,14,15). (U.S. Patent #4,845,729,
assignee: Elex Analytical Technologies Corporation,
Upton, NY 11973). Partially polarized photons are di-
rected at the subcutaneous, medial midtibial cortical
bone. The LXRF spectrum, measured 900 from the in-
cident beam, reveals a peak in the 10.5 KeV region,
which represents the lead La line. To correct for at-
tenuation of photons by pretibial soft tissue, thickness
measurements were carried out ultrasonically.
The average skin dose, deliberately limited to 1 rad
over a
- 4 cm2 area, was delivered in 16.5 min (Table
1). The effective dose equivalent was calculated to be
S 2.5microsieverts, about 1/10thto 1/20th ofone dental
X-ray and about 1/25th of that from one radiographic
examination ofthe chest (13,14,15). This effective dose
equivalent is < 0.1% of the average annual effective
dose equivalent for an individual in the U.S. population
from natural background radiation sources. Within the
same population, therefore, LXRF measurements of
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Table 1. LXRF technique: noninvasive detection of bone lead in
vivo using polarized radiation.
Table 2. Criteria for validation and clinical assessment of LXRF
measurements in lead-toxic children (13,14,15).
X-ray generator
Voltage
Current
X-ray tube anode
Detection system
X-ray detector
Patients
Age
Exposed area
Imparted energy
Effective dose
equivalent
Counting time
Soft tissue (skin)
thickness over the
medial surface of
the tibia
Minimum detection limit
Day-to-day instrument
reproducibility
In vivo reproducibility of
replicate measurements
in 26 lead-toxic children
50 kVp
30 mA
Ag
(Closed system;
without significant
scattering)
Si (Li)
1-6 years
-4 cm2
0.1 mJ (-1/10-1/20
of dental X-ray)
S 2.5 ,uSv (-1/20-1/25
of chest X-ray)
16.5 min
3-8 mm (median, 5 mm)
7 ,ug lead/g of bone with
5 mm of skin thickness
± 5.1 % (95% confidence
interval)
± 9.2% (95% confidence
interval)
the tibia are much less risky than those dental and pul-
monary radiological examinations that are performed
routinely. Because this instrumentation was designed
as an essentially closed system, a parent can be present
during the LXRF examination with negligible risk from
scattered radiation. The reproducibility of replicate
LXRF measurements in 26 lead-toxic children, after
repositioning the instrument within 4 cm of the first
LXRF measurement, was + 9.2% (95% confidence
limit) (13,14).
To quantify X-ray attenuation by overlying soft tis-
sue, the net 16.5-min photon count in the lead La peak
from the medial aspect of the tibia of nine adult sur-
gically amputated specimens was recorded before and
after removal ofepitibial soft tissue. An average effec-
tive exponential attenuation coefficient (0.45 + 0.06
mm-1, mean + SEM) was calculated from the resultant
nine photon count ratios (13,14). Similar results were
obtained from regression and analyses of these ratios
with respect to soft tissue thickness (15). The average
concentration of lead in the full cross-section of tibial
bone subjacent to the area of LXRF examination was
measured by several flameless atomic absorption mea-
surements of dissolved bone from each of nine ampu-
tated specimens. The correlation coefficient (r value)
between LXRF measurements of bare bones and the
average value of atomic absorption analyses of two full
cross-sections of each specimen was 0.92 (15). The rel-
ative standard deviation for 18 measurements of bone
lead samples by flameless atomic absorption spectros-
copy (AAS) was + 5.1% (95% confidence limits). The r
value between LXRF measurements ofintact limbs and
AAS measurements of the bone lead samples was 0.95
Parameter
Clinical relevance
Dosimetry
Closed system
Parent in attendance
Reproducibility of instrument
Reproducibility in lead-toxic children
AAS versus LXRF (surgically removed
limbs)
Minimum detection limit
Exponential attenuation coefficient
Photon count ratios
Regression analysis
Pregnancy-dosimetry (16)
Further improvements in system
Counting time
Lead/strontium ratios
Minimum detection limit
Carried out In progress
X
X
X
X
X
X
X
X
X
X
X
(15). The average value of the ratio of the tibial bone
lead concentration, in micrograms per gram, to the net
corrected LYP'F photon count, normalized to the me-
dian skin t. ;kness of 5 mm, was 0.09 ± 0.01 (RugIgl
count, mean ± SEM). For this skin thickness, the min-
imum detection limit was estimated to be 7 ,ug lead/g
(wet weight) at the 95% confidence interval (13,14,15).
Based upon clinical research data already published
(13,14), sequential LXRF data presented herein and a
detailed study of the physics and calibration of the
LXRF instrument (15), the validation and diagnostic
applicability of this new technique have been estab-
lished in lead-toxic children (Table 2). Nonetheless, fur-
therinstrument improvements to decrease the counting
time and enhance the minimum detection limit (MDL)
below 7 ,ug lead/g of bone can be anticipated by modi-
fying the geometry of the detector and using different
polarizing materials (Table 2). Dosimetry measure-
ments have also been carried out to assess the safety
ofLXRF measurements during pregnancy. These data
indicate- that one or two LXRF measurements during
pregnancy is equivalent to the natural background ra-
diation dose that the fetus is exposed to during 15 min
of normal gestation (16).
Results
Based upon home visits and objective assessments of
the quality of housing of these Bronx children, their
ages, andtheirPbB, EP, andurinarylead-CaNa2EDTA
ratios (PbU/EDTA), these lead-toxic childrenwererep-
resentative of the majority of children attending lead-
toxicity programs nationally. The CaNa2EDTA-posi-
tive children had higher PbB, EP, and net corrected
LXRF photon counts compared to the CaNa. EDTA-
negative children (Table3) (13,14). Valuesforbonelead,
corrected for 5 mm ofoverlying soft tissue in all study
children, wereabouttwotimesgreaterinCaNa2EDTA-
positive than in CaNa2EDTA-negative children.
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Table 3. PbB, EP, PbU/CaNa2EDTA values, and net corrected LXRF values in lead-toxic children (13,14).
Corrected LXRF valuesa'b
CaNaIEDTA Ratio of Net Bone PbC
test result Age, months PbB, ,ug/dL EP, ,ig/dL PbU/CaNa2EDTA photon counts ,g Pb/g
Negative 33 ± lod 30 ± 5d 89 ± 43d 0.39 ± 0.13d 159 ± 20e 14 ± 2e
(n = 30)
Positive 38 ± 15* 39 ± 8* 115 ± 65t 0.95 ± 0.27t 309 ± 52* 29 ± 4*
(n = 29)
aCorrected according to the day-to-day reproducibility of the instrument.
bCorrected to 5 mm of overlying skin thickness. The normalization of these data to a standard epitibial soft tissue thickness of 5.0 mm in
this table was carried out, but does not pertain to Table 2 (13,14).
'Normal adult values for tibial lead are 19-27 ,ug Pb/g (17,18). Values for tibial lead in adult workers in lead industries are ¢ 30 pg Pb/g
(17,18).
dMean ± SD.
eMean ± SEM.
* p < 0.001 versus CaNa2EDTA-negative group.
tp < 0.01 versus CaNa,EDTA-negative group.
Table 4. Statistical analyses of net corrected LXRF photon counts, PbB, EP,
and CaNa2EDTA test results from 59 lead toxic children (13,14).
Pearson Analysis of tests
correlation
coefficients LXRF/PbB LXRF/EP LXRF/CaNa2EDTA PbB/CaNa2EDTA PbB/EP
r 0.388 0.200 0.472 0.701 0.499'
p <0.003 > 0.010 <0.001 <0.001 <0.001
Correlation coefficients other than the correlation be-
tween LXRF and EP were statistically significant (Ta-
ble 4) (13,14). Discriminant function analysis was car-
ried out by entering corrected LXRF counts, PbB, EP,
and age in a stepwise manner with the CaNa2EDTA
test result as the categorical criterion variable. Based
upon this analysis, 90% oflead-toxic children were pre-
dicted correctly as being CaNa2EDTA-positive or
CaNa2EDTA-negative. Neitherage norEPcontributed
to the power of the discriminant analysis. In a retro-
spective analysis of 59 similar lead-toxic children from
our clinic using the indices of EP and PbB to predict
CaNa2EDTA outcomes, 78% ofchildren were correctly
categorized. Hence, by including bone lead measure-
ments by LXRF, which has a high discriminant power
alone, an additional 190,000 to 650,000 lead-toxic chil-
dren in the U.S. could be correctly categorized and ap-
propriately managed medically. By using net corrected
LXRF counts and PbB values to predict CaNa2EDTA
outcomes, the specificity and sensitivity of these two
Table 5. CaNa2EDTA test outcomes compared to predicted
outcomes from a discriminant analysis using corrected LXRF
photon counts and PbB values as independent variables (13,14).a
Predicted
Actual CaNa2EDTA CaNa2EDTA outcomes
test results + -
+ 28 2
4 25
aBy using net corrected LXRF photon counts and PbB to predict
CaNa2EDTA test outcomes, the specificity [true negative (-) (n =
25)/true negative (-) plus false positive (+) (n = 29)] was 86% and
the sensitivity [true positive ( +) (n = 28)/true positive (+) plus false
negative (-) (n = 30)] was 93%.
predictors were 86 and 93%, respectively (Table 5)
(13,14). In 20 and 24% of CaNa2EDTA-negative and
CaNa2EDTA-positive children, respectively, cortical
bone lead values were similar to lead concentrations
measured in bone biopsies from normal adults (17,18).
Remarkably, an additional 40% of CaNa2EDTA-posi-
tive children had bone lead concentrations observed in
industrially exposed adults (17,18).
In this longitudinal study, lead-toxic children who did
not qualify fortreatment and other children who under-
went one or two courses of CaNa2EDTA treatment
were re-evaluated 6 weeks and 24 weeks postenroll-
ment. By 24 weeks, PbB, EP, and PbU/EDTA ratios
were very similarin all three groups (Figs. 2A-C). The
most dramatic decreases in net corrected photon counts
by LXRF occurred in children treated twice. In addi-
tion, there was a gradual and progressive dissociation
between PbB, EP, or PbU/EDTA ratios and sequential
measurements of bone lead by LXRF (Fig. 2D).
Mean values of cortical bone lead by LXRF at 24
weeks in all three groups ofchildren were similar to the
mean concentration inuntreated CaNa2EDTA-negative
children at enrollment and still three to five times
greater than those measured in the tibia or whole teeth
of normal European children using AAS (19-22). In
lead-toxic children who did not qualify for treatment,
additional significantaccumulationofleadinbone ended
once children were removed from leaded environments
and/or returned to lead-abated apartments (Fig. 2D).
Discussion
The development and clinical validation of K-line
XRF instruments inindustriallyexposed adults (23-24)
and the L-line XRF technique in lead-toxic children
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BLOOD LEAD CONCENTRATIONS
BY TREATMENT GROUP
0 WEEKS 6 WEEKS 24 WEEKS
TIME
A
URINARY Pb / CaNa EDTA RATIO
BY TREATMENT GROUP
0 WEEKS 6 WEEKS 24 WEEKS
TIME
C
EP CONCENTRATIONS
BY TREATMENT GROUP
CL
TIME
B
L - XRF
BY TREATMENT GROUP
z
D
0
LU
z
0
0
0 WEEKS 6 WEEKS 24 WEEKS
TIME
D
FIGURE 2. Sequential values for (A) PbB, (B) EP, (C) PbU/EDTA ratios, and (D) net corrected LXRF counts are shown in children at
enrollment and 6 weeks and 6 months after enrollment. Rx = 0 indicates lead-toxic children who did not qualify for CaNa2EDTA treatment;
Rx = 1 represents children treated with one inhospital course of a CaNa2EDTA after obtaining baseline values at enrollment; and Rx =
2 indicates lead-toxic children treated in the hospital with CaNa2EDTA after baseline values were obtained at enrollment and again 6 weeks
postenrollment.
(13,14,15) open exciting and highly relevant time win-
dows of several months to several years to assess the
impact oflarge bone reservoirs oflead on human health.
These two XRF approaches to measure lead in bone
are likely to shed further understanding on the biolog-
ical information obtained by measuring lead in whole
blood (6). The LXRF technique also presents a possi-
bility for resolving long-standing uncertainties concern-
ing fetal exposure to lead in relation to maternal lead
stores. Moreover, XRF techniques may explore epi-
demiological connections between hypertension (25) and
osteoporosis (26).
It is clear from previous work that concentrations of
lead in bone (long bones and tooth dentine) correlate
closely with the presence oflead nephropathy in adults
(27) and neurobehavioral and cognitive impairments in
children (20,22,28) (Table 6). Furthermore, during non-
steady-state conditions (growth, pregnancy, lactation,
demineralization of the skeleton), it is reasonable to
expect that the metabolism of lead in bone is related
more closely to skeletal remodeling and recycling rates
than to chemical differences between lead and calcium.
In this study of 59 lead-toxic children, the clinical
relevance and diagnostic capability of the LXRF tech-
50
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0
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Table 6. Cortical bone lead values in children.
Reference Subjects Mean, ppm wet weight
Barry (19) Normals 3
Winnecke (20) Normals 3-5
Grandjean (21) Normals 3-5
Needleman (29) Lead poisoned - 31
Winnecke (22) Smelter exposed - 12
Rosen et al. (13,14) Lead toxic
(by LXRF) CaNa2EDTA (-) 14
CaNa2EDTA (+) 29
nique have been proven. A PbB determination and
LXRF measurement were predictive ofthe need for in-
hospital chelation therapy in 90% oflead-toxic children
(PbB: 25-55 ,ug/dL; EP
- 35 ,ug/dL). By including bone
lead measurements by LXRF, several additional thou-
sands oflead-toxic U.S. children annually could be cor-
rectly categorizedandappropriatelymanaged medically
(1). Moreover, the capability of the LXRF technique
may be applied even more widely as considerations are
given to lowering the current Centers for Disease Con-
trol's definition of an elevated PbB value as ¢ 25 ,ug/
dL. In this regard, at mean PbB values of 33 and 38
,ug/dL in CaNa2EDTA-negative and CaNa2EDTA-pos-
itive children, respectively, a majority of children in
both groups, by 6 years of age, have already achieved
boneleadvaluesmeasuredinnormaladultsandworkers
inleadindustries. Wesurmisethateitheranexcessively
narrow margin of safety or insufficient safety is pro-
vided by current U.S. guidelines, which define an ele-
vated PbB as
- 25 ,ug/dL.
Other results indicated that neither age nor EP con-
tributed to the power of the discriminant analysis; a
significant though modest correlation was observed be-
tween bone lead values by LXRF and PbB concentra-
tions in untreated children. In children 6 months after
enrollment who were untreated, treated once, or
treated twice (Figs. 2A-C), PbB, EP, and PbU/EDTA
ratios returned to values currently considered to be
normal. In contrast, tibial cortical bone lead concentra-
tions remained three to five times higher than concen-
trations in compact tooth bone in normal European chil-
dren (19-22) (Fig. 2D). These high bone lead values, at
the end point of so-called successful chelation therapy,
may prove to be of considerable public health signifi-
cance as some ofthese children become women ofchild-
bearing age. Elevated bone lead values accumulated
during early childhood may have an intergenerational
impact, as these maternal lead stores cross the placenta
and impact directly on the developing fetus.
These dataindicatethat LXRF measurements oflead
in cortical bone may have the potential to replace the
cumbersome, impracticalCaNa2EDTAtest. Ourresults
also suggest that LXRF measurements oflead in bone
mayultimately proveto be amore appropriate endpoint
ofchelationtherapy thanthe conventionalindices: PbB,
EP, and PbU/EDTA. We speculate that LXRF mea-
surements may prove to be useful predictors ofthe re-
sults of neurobehavioral parameters in lead-toxic chil-
dren after chelation therapy.
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